1776 YORKTOWN, HOUSTON, TX
Annual Report to Security Holders
Nexalin Technology Adopts Second Amended and Restated Bylaws
Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and NeuroCare™ Ahead of Planned FDA Pivotal Trial
Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment
Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market
Technology Receives Nasdaq Listing Status Notification
Harnessing the Power of Advanced Frequency Neurostimulation to Improve Mental Health Investor Presentation | December 2025
Amendment No. 2 to Equity Distribution Agreement - Nexalin Technology, Inc.
FY 2025
Q3
Amended Annual Report
Q2
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Direct Registration System
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Correspondence
Deregistration Letter
Submission Upload